Home

TLDR Biotech

The top stories in biotech & pharma, straight to your inbox in only one email.
Trusted by 3000+ biotech and pharma professionals.

Comprehensive daily coverage of the biotech and pharma industry, straight to your inbox.

TLDR Biotech

The Latest Biotech & Pharma Updates

Biotech & Pharma Updates | October 23, 2026

Oct 23, 2026

•

3 min read

Biotech & Pharma Updates | October 23, 2026

🧬 Gilead Sciences acquires PepStar Therapeutics' IL-23R inhibitor program for $1.3B upfront, Alnylam plans pivotal trial for brezosiran (ALN-HTT02) targeting huntingtin protein in Huntington's disease after Ph1b success, FDA lifts clinical hold on Aardvark Therapeutics' ARD-101 after new cardiac safety data clears concerns

Christian Cuchapin, +1

Biotech & Pharma Updates | October 22, 2026

Oct 22, 2026

•

3 min read

Biotech & Pharma Updates | October 22, 2026

🧬 Roche's Vabysmo hits $1.38B quarterly sales, meets analyst expectations after prolonged growth slowdown, AstraZeneca's Ultomiris (ravulizumab) wins FDA accelerated approval for immunoglobulin A nephropathy, its fifth indication, FDA accepts Biohaven's Vyglxia (troriluzole) resubmission for spinocerebellar ataxia with advisory committee meeting planned

Christian Cuchapin, +1

Biotech & Pharma Updates | October 21, 2026

Oct 21, 2026

•

3 min read

Biotech & Pharma Updates | October 21, 2026

🧬 GSK, Ionis Pharmaceuticals win FDA approval for Hibsago (bepirovirsen) targeting hepatitis B virus in chronic hepatitis B infection following Ph3 success, Priovant Therapeutics seeks label expansion for Lisraya (brepocitinib) after Ph3 success in non-infectious uveitis, OpenAI acquires Orchestra Bio, combining AI platforms to accelerate drug development workflows

Christian Cuchapin, +1

Biotech & Pharma Updates | October 20, 2026

Oct 20, 2026

•

3 min read

Biotech & Pharma Updates | October 20, 2026

🧬 GSK's Jemperli (dostarlimab) receives FDA accelerated approval for MSI-H/dMMR locally advanced rectal cancer based on Ph2 data, Eli Lilly, METiS TechBio partner on AI-driven LNP drug delivery platform, up to $1.1B milestones, Gilead Sciences' (emvistegrast) meets Ph2 primary endpoint in moderately to severely active ulcerative colitis, Ph3 planned

Christian Cuchapin, +1

Biotech & Pharma Updates | October 19, 2026

Oct 19, 2026

•

3 min read

Biotech & Pharma Updates | October 19, 2026

🧬 Merck KGaA acquires Silence Therapeutics for $1.3B, gaining promising siRNA blood cancer drug divesiran, Disc Medicine's (bitopertin) Ph3 trial meets all endpoints for erythropoietic protoporphyria, paving way for FDA resubmission, Sanofi breaks ground on new Frankfurt insulin manufacturing facility, targeting full production by 2032

Christian Cuchapin, +1

The Diseases We Couldn't Afford to Study Until Now

Oct 17, 2026

•

4 min read

The Diseases We Couldn't Afford to Study Until Now

Deciding which diseases are worth studying has never been a purely scientific question. It has always come down to how much evidence one person can hold in their head. AI is changing that.

Anis Fahandej-Sadi

Biotech & Pharma Updates | October 16, 2026

Oct 16, 2026

•

3 min read

Biotech & Pharma Updates | October 16, 2026

🧬 Roche's Enspryng (satralizumab) wins FDA approval for thyroid eye disease, targeting interleukin-6 receptor following Ph3 data, City Therapeutics raises $200M IPO, advancing next-gen RNAi therapies pipeline, Eli Lilly's oral weight-loss pill Foundayo wins EU regulator backing for obesity and type 2 diabetes

Christian Cuchapin, +1

Biotech & Pharma Updates | October 15, 2026

Oct 15, 2026

•

3 min read

Biotech & Pharma Updates | October 15, 2026

🧬 Iambic Therapeutics raises $150M IPO, AI-driven drug discovery targeting HER2-positive solid tumors, FDA expands ImmunityBio's Anktiva (nogapendekin alfa inbakicept-pmln) label for high-grade papillary non-muscle invasive bladder cancer, AstraZeneca, Insitro partner on MASH and cardiomyopathy drug discovery, $40M upfront, $1.5B total

Christian Cuchapin, +1

Biotech & Pharma Updates | October 14, 2026

Oct 14, 2026

•

3 min read

Biotech & Pharma Updates | October 14, 2026

🧬 Zealand Pharma, Generate:Biomedicines partner on AI-designed obesity, metabolic drugs, up to $1.2B deal, Verastem Oncology's (VS-7375) shows 50% objective response rate in Ph1/2 for KRAS G12D-mutant metastatic pancreatic ductal adenocarcinoma, Soufflé Therapeutics raises $135M Series A to advance three cell-targeted RNA programs into clinic

Christian Cuchapin, +1

...

The Latest Biotech & Pharma Updates

Biotech & Pharma Updates | October 23, 2026

Biotech & Pharma Updates | October 22, 2026

Biotech & Pharma Updates | October 21, 2026

Biotech & Pharma Updates | October 20, 2026

Biotech & Pharma Updates | October 19, 2026

The Diseases We Couldn't Afford to Study Until Now

Biotech & Pharma Updates | October 16, 2026

Biotech & Pharma Updates | October 15, 2026

Biotech & Pharma Updates | October 14, 2026

TLDR Biotech

FAQ

Media Partners